Laurence Albigès, MD, PhD, on Key Findings With Nivolumab/Cabozantinib in Advanced RCC
March 27th 2022Laurence Albigès, MD, PhD, spotlighted 2-year follow-up data from the phase 3 CheckMate 9ER trial, which looked at nivolumab and cabozantinib in patients with previously untreated advanced or metastatic renal cell carcinoma.